

Press Release

For Immediate Dissemination

Glenmark Pharmaceuticals announces the settlement of Paragraph IV litigation with Forest Laboratories

Mumbai, December 21, 2015: Glenmark Pharmaceuticals Inc., USA and Glenmark Pharmaceuticals Ltd. (“Glenmark”) announced that they have entered into a Settlement Agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd., and Royalty Pharma Collection Trust to settle and dismiss the outstanding patent litigation related to Glenmark’s Abbreviated New Drug Application for Milnacipran Hydrochloride 12.5 milligram, 25 milligram, 50 milligram, and 100 milligram tablets, the generic version of Forest’s Savella®.

Under the terms of the Settlement Agreement, Glenmark will have the option to market and distribute its Milnacipran Hydrochloride tablets or an authorized generic version of Savella® tablets. Other terms of the Settlement Agreement are confidential.

According to IMS Health sales data for the 12 month period ending October 2015, Savella® achieved annual sales of approximately \$134.7 million*.

Glenmark’s current portfolio consists of 103 products authorized for distribution in the U.S. marketplace and 63 ANDA’s pending approval with the U.S. FDA. In addition to these internal filings, Glenmark continues to identify and explore external development partnerships to supplement and accelerate the growth of its existing pipeline and portfolio.

All brand names and trademarks are the property of their respective owners.

**IMS Health National Sales Perspectives: Retail & Non-Retail, October 2015*

About Glenmark

Glenmark Pharmaceuticals Ltd. (GPL) is a research-driven, global, integrated pharmaceutical company headquartered at Mumbai, India. It is ranked among the top 80 Pharma & Biotech companies of the world in terms of revenues. (SCRIP 100 Rankings published in the year 2014). Glenmark is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity). Glenmark has several molecules in various stages of clinical development and is primarily focused in the areas of Inflammation [asthma/COPD, rheumatoid arthritis etc.] and Pain [neuropathic pain and inflammatory pain].

The company has a significant presence in branded generics markets across emerging economies including India. GPL along with its subsidiary has 16 manufacturing facilities in four countries and has six R&D centers. The Generics business of Glenmark services the

requirements of the US and Western Europe markets. The API business sells its products in over 80 countries, including the US, various countries in the EU, South America and India.

For further information, please contact:

Jason D'Souza / Rajdeep Barooah

Glenmark, Mumbai, India

Tel: [+91 22] 40189919/984

Email: corpcomm@glenmarkpharma.com